Valve's MOBA hero shooter Deadlock is still in an invite-only testing phase, as the company continues to develop and iterate. But a recent livestream mix-up looks like it revealed the existence of ...

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in ...

Half-Life 3 remains one of the gaming world's biggest mysteries. Everyone knows, Valve included, that there is a deep desire to see another entry in the FPS series, even after all this time.

Virtual Reality & Augmented Reality Valve deckard VR headset described as ‘quite amazing’ but there’s still no word on its launch Virtual Reality & Augmented Reality Forget Android XR ...

There've certainly been a lot of Valve Deckard rumours over the last couple of years, but this one, at least, seems more tangible than previous ones referencing driver files and so on, because it ...

In the 1970s and ‘80s, traces of the artist collective Asco, named after the Spanish word for “disgust,” could be seen all over East L.A. The then-teenage creatives pulled all kinds of high ...

Valve’s Index headset was a market leader among PC VR headsets for years, but is it still worth buying in 2025 now that it’s nearly six years old? Read on for our no-nonsense recommendation.

They called themselves Asco, the Spanish word for nausea or revulsion. Then, a little more than a decade on, Asco vanished. Almost. The new documentary ASCO: Without Permission, premiering at ...

Valve's new headset is reported to cost $1,200 in a bundle The company is allegedly selling the headsets at a loss Sources claim you'll be able to play Steam Deck games on it The upcoming Valve VR ...

The preliminary results of this study were presented at the 2024 ASCO Annual Meeting and led to widespread attention and discussion among experts worldwide. The updated data at ASCO GU further ...

ASCO GU symposium focuses on antibody-drug conjugates, biomarker advancements, and disparities research in genitourinary cancers. TALAPRO-2 trial results highlight talazoparib and enzalutamide as ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU ...